Quantitation of Human Cerebral Nicotinie Receptors With 2[18F]FA-85380 and PET Healthy Non-smokers and Ex-Smokers and in Heavy and Light Situational Smokers
NCT01038245 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 72
Last updated 2017-07-02
Summary
Background:
\- Central nicotinic acetylcholine receptors (nAChRs) are primary targets for the action of nicotine. In addition to being involved in tobacco dependence, they are also involved in a variety of brain disorders, including Alzheimer's and Parkinson's diseases. Researchers are interested in developing better ways to study the action of nAChRs to improve treatments for smoking cessation and other problems affected by these receptors. These new study methods may involve different approaches to positron emission tomography (PET) scanning, which can show brain activity related to nAChRs.
Objectives:
\- To evaluate appropriate and useful doses of radiotracers used in PET scanning of nAChRs in the brains of nonsmokers/former smokers, light smokers, and heavy smokers.
Eligibility:
\- Individuals between 18 and 50 years of age who fall into one of the following groups: (1) nonsmokers or former smokers who have not smoked for the past 2 years, (2) light/situational smokers, or (3) heavy smokers (at least 15 cigarettes/day for the past 2 years).
Design:
* Each participant will undergo up to three PET studies, given approximately1 month apart. Each study will take approximately 8 hours to complete.
* Participants will provide urine and breath samples before the study and at the start of the study, which will be tested for chemicals that may interfere with the study.
* Depending on the study, some of the smoking participants may receive a nicotine patch to wear during the PET scan.
* On the day of the study, participants will receive a dose of a radiotracer (a drug used in PET scanning) given either as a single injection or as an injection followed by a continuous infusion, and will have a series of PET scans over the next 7 hours and provide blood samples during that time.
* Participants will return for a follow-up visit 1 month after the end of the study.
Conditions
- Nicotine Addiction
Sponsors & Collaborators
-
National Institute on Drug Abuse (NIDA)
lead NIH
Eligibility
- Min Age
- 18 Years
- Max Age
- 50 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2003-07-08
- Completion
- 2011-11-18
Countries
- United States
Study Locations
More Related Trials
-
Effect of Orexin System on Nicotine Addiction and Its Neural Mechanism
NCT05947162 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Nicotinic Hepatic Metabolism on Neuroreceptor Substrates of Nicotine Addiction
NCT03442413 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Effect of Nicotine on Brain Reward Pathways
NCT02346539 ·Status: COMPLETED ·Phase: PHASE1
-
Understanding Factors That Influence Electronic Cigarette Nicotine Delivery Through PET Imaging of Beta-2 Nicotinic Acetylcholine Receptors
NCT04258852 ·Status: WITHDRAWN ·Phase: NA
-
Impact of Varenicline on Blood-Oxygen-Level Dependent (BOLD) Functional Magnetic Resonance Imaging (fMRI) Activation on Smokers
NCT00934024 ·Status: COMPLETED ·Phase: NA
-
Brain Nicotine Receptor Density in Veteran Smokers
NCT01721473 ·Status: COMPLETED
-
Assessing Top Down and Bottom Up Attention Mechanisms in Smokers Using Nicotine Nasal Spray
NCT01136642 ·Status: COMPLETED ·Phase: PHASE1
-
Nicotine Withdrawal Symptoms and Smoking Relapse
NCT01511614 ·Status: COMPLETED ·Phase: NA
-
Effects of Nicotine on Elements of Attentions in Smokers and Nonsmokers
NCT01034020 ·Status: COMPLETED ·Phase: PHASE1
-
Nicotine Receptor Levels and Smoking Cessation
NCT01788943 ·Status: COMPLETED
-
Brain Nicotine Receptor Density & Response to Nicotine Patch
NCT01526005 ·Status: COMPLETED
-
Nicotine Metabolizers and [11C]-(+)-PHNO
NCT02514720 ·Status: COMPLETED ·Phase: NA
-
Translational Neuropsychopharmacology Research of Nicotine Addiction
NCT02723162 ·Status: COMPLETED ·Phase: PHASE2
-
Effect Of Nicotine on Neurocognitive Performance of Cigarette Smokers
NCT00429208 ·Status: UNKNOWN ·Phase: NA
-
Effect of Varenicline on Tobacco Addiction and on Abstinence-induced Cognitive Impairment
NCT01309685 ·Status: WITHDRAWN ·Phase: PHASE1
-
Effects of Varenicline on Brain Activity During Nicotine Abstinence
NCT00602927 ·Status: COMPLETED ·Phase: NA
-
Mechanisms of Lorcaserin for Smoking Cessation
NCT04396834 ·Status: TERMINATED ·Phase: PHASE2
-
Effectiveness of N-Acetylcysteine (NAC) in Motivational Enhancement Therapy for Nicotine Addiction
NCT05903014 ·Status: COMPLETED ·Phase: PHASE4
-
Measuring Neuroadaptations in Response to Very Low Nicotine Content Cigarettes
NCT03612960 ·Status: COMPLETED ·Phase: NA
-
Brain Reaction to Treatment of Nicotine Dependence
NCT00108173 ·Status: COMPLETED ·Phase: PHASE1
-
A Multi-Modal Investigation of the Smoking Cessation Medication Varenicline: Dopaminergic Modulation of Reward Processing and Cognitive Control
NCT00830739 ·Status: COMPLETED
-
Effects of Smoking Environments on Brain Reactivity
NCT03421210 ·Status: COMPLETED ·Phase: PHASE4
-
Functional Magnetic Resonance Imaging (fMRI) Investigation of Nicotine Withdrawal Symptoms
NCT00657020 ·Status: COMPLETED ·Phase: PHASE4
-
Varenicline on Reward Responses and Cognition in Adolescent Smokers
NCT01624428 ·Status: COMPLETED ·Phase: PHASE1
-
Effects of Varenicline on Smoking Reminders
NCT01524627 ·Status: COMPLETED ·Phase: PHASE2